Received: February 25, 2009
Accepted: April 12, 2009
Ref: Xu S, Li X, Shen X, Guo X, Peng Y, Liu Y, Zhao Q, Feng S, Wang F. Activation of NF-κ B signalling pathway by inflammatory regulators and associated drug discovering. Internet J Med Update 2010 Jul;5(2):38-44.
ACTIVATION OF NF-κ B SIGNALLING PATHWAY BY INFLAMMATORY REGULATORS AND ASSOCIATED DRUG DISCOVERING
Dr. ShiQin Xu*, Dr. XiaoHong Li*, Prof. XiaoFeng Shen*, Prof. XiRong Guo**, Prof. YuZhu Peng**, Dr. YuSheng Liu*, Dr. QingSong Zhao*, Dr. ShanWu Feng* and Dr. FuZhou Wang*
*Department of Anesthesiology and Critical Care, Affiliated Nanjing Maternity and Child Health Care Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
**Institute of Pediatrics, Affiliated Nanjing Maternity and Child Health Care Hospital, Nanjing Medical University, Nanjing, Jiangsu, China
(Corresponding Author: Dr. FuZhou Wang, Department of Anesthesiology and Critical Care, Affiliated Nanjing Maternity and Child Health Care Hospital, Nanjing Medical University, No. 123, Tianfei Xiang, Mochou Road, Nanjing 210004, Jiangsu, China. Email: email@example.com)
Intracellular signalling transduction plays a pivotal role in cell activation, and the regulation of gene transcription needs the involvement of series of nuclear factors. Nuclear transcription factor- kappa B, one of the key factors in mediating gene expression, takes an essential part in a body of physiological and pathological processes. Endotoxin lipopolysaccharides, proinflammatory cytokine tumor necrosis factor-alpha, ligand-dependent immunocellular B cell receptor and inflammation-associated bradykinin are four typical NF-κB activation pathways. Activating or inhibitory drugs focused on NF-κB may be strongly related with the therapy of associated diseases, and the exploration of effective and economical drugs concentrated on NF-κB is crucial.
KEY WORDS: Nuclear factor-κB; Inhibitor factor-κB; Inflammatory signalling; Drug discovery